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Abstract: Procedures for the treatment of retinal detachment and related conditions have 
been successfully improved upon in recent years thanks to the advent of new therapies and 
biomaterials. This review, after giving an overview on eye structure and function, focuses 
on the treatment of retinal detachment and examines the role and features of the materials 
used in vitreoretinal surgery, emphasizing scleral buckling and short-term/long-term 
vitreous tamponade. Specifically, the limitations of existing biomaterials are underlined, 
based on experimental studies and with particular reference to cells/material interactions. 
Finally, current and future trends of biomaterials‘ research in the field of vitreoretinal 
surgery are considered and discussed. 
Keywords: retina; vitreous; scleral buckling; vitreous substitute; silicone; hydrogel 
 
1. Introduction 
The human eye is a complex organ of vital importance for everyday life. The risk of retinal 
detachment (RD) in otherwise normal eyes has been estimated at about 0.005% and is more frequent in 
middle-aged or elderly people [1,2]. The fate of the eyes affected by RD, if not properly treated, is a 
progressive loss of vision over time and, eventually, complete blindness. Ocular biomaterials and 
implants have been successfully used in order to enable surgeons to restore vision in ever more 
complex RD cases [3–6]. The first part of this article provides an overview of eye anatomy and 
physiology, which should be useful to non-specialist readers. Afterwards, the RD features and the 
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clinical use of materials in RD treatment are examined. Specifically, the suitability, advantages and 
drawbacks of the polymeric materials currently in use are outlined and discussed and, finally, a forecast 
for the future is presented. 
2. Anatomy and Physiology of the Eye: Short Overview 
The eye is a highly specialized organ devoted to the conversion of photons into spatially organized 
and temporally resolved electrochemical signals. The main features of eye anatomy, which is briefly 
described in the following sections, are shown in Figure 1. 
Figure 1. Schematic of the eye showing essential features and elements. 
 
2.1. Basic Concepts 
The ocular globes, usually named eyeballs, are housed in two proper cone-shaped sockets, termed 
orbits, within the skull [6]. The orbit size exceeds the size of the eyeball by a considerable margin and 
the space between bone and ocular globe is filled by fatty tissue. The eyeball is lined with a sheet of 
connective tissue named Tenon‘s capsule, which aims to provide a smooth socket for allowing the free 
movement of the ocular globe. The outer walls of the eye are formed by two distinct tissue layers, the 
cornea and the sclera. Six extraocular muscles attach to the outer sclera serving to rotate the eye 
according to desired movements. The corneoscleral envelope forms a closed shell, pierced at the back 
of the eye by the scleral canal, through which the optic nerve leaves the eye itself. Light enters the eye 
through the cornea; then traverses the anterior chamber containing the aqueous humor, the pupil, the 
crystalline lens and the vitreous body, before striking the retina. The crystalline lens is suspended by 
ligaments known as zonules, which attach to inner fibers of the ciliary muscle. Variations in the tone of 
these muscle fibers allow the zonules to tug on the lens, so that it can change shape to alter the focal 
length of the eye in the course of visual accommodation. The ciliary body consists of the ciliary muscle 
and a highly folded and vascularized inner layer, known as ciliary processes, which secrete a colorless 
fluid named aqueous humor. This fluid bathes the crystalline lens, flows through the pupil to fill the 
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anterior chamber and finally nourish the cornea, before draining out of the eye through specialized 
tissues at the boundary between iris and cornea. Aqueous humor creates a positive pressure within the 
eye, the intraocular pressure (IOP). The retina covers about two-thirds of the inner surface of the 
posterior chamber, i.e., the space behind the lens (Figure 1), which is filled with a transparent 
gelatinous solid (vitreous body).  
2.2. The Vitreoretinal System 
The posterior chamber of the eye consists of three distinct layers, the sclera, the choroid and the 
retina, surrounding the vitreous body (Figure 1). The sclera is a protective coat of connective tissue, 
whereas the choroid is a highly vascularized tissue providing the blood supply to retinal cells. 
2.2.1. Retina 
The retina is composed of nerve tissue that senses the light entering the eye; the retinal layer is 
separated from the choroid by Bruch‘s membrane. From a structural viewpoint, the retina can be 
divided in 10 sub-layers from the outside (adjacent to Bruch‘s membrane) to the inside (adjacent to the 
vitreous body) [7,8]: (i) retinal pigment epithelium (RPE), (ii) outer segments of photoreceptors, (iii) 
inner segments of photoreceptors, (iv) outer nuclear layer (cell bodies of photoreceptors), (v) outer 
plexiform layer (photoreceptors axons, horizontal cells‘ dendrites, bipolar dendrites), (vi) inner nuclear 
layer (bodies of horizontal, bipolar and amacrine cells), (vii) inner plexiform layer (axons of bipolar 
and amacrine cells, dendrites of ganglion cells), (viii) ganglion cells layer, (ix) nerve fibers layer 
(axons from ganglion cells traversing the retina to leave the eye at the optic disc), (x), internal limiting 
membrane, that separates the retina from the vitreous body. 
The photoreceptors are the sensing elements of the retinal layer and can be divided into cones and 
rods. The outer segment of photoreceptors contains light-sensitive proteins belonging to the group of 
opsins. Cones and rods are sensitive to different visual conditions as they are characterized by two 
different pigment molecules and, therefore, by two different light-sensitive proteins, iodopsin and 
rhodopsin, respectively [9]. Specifically, light causes a chemical reaction with iodopsin in cones, 
activated in photopic or bright conditions, and with rhodopsin in rods, activated in scotopic or dark 
conditions. Activated photoreceptors stimulate bipolar cells, which in turn stimulate ganglion cells; the 
impulses run along the axons of the ganglion cells, then through the optic nerve and towards the visual 
centre at the back of the brain, where the image is perceived as right-side up. 
There are about 6.5 to 7 million cones in each eye, and they are sensitive to bright light and to color. 
The cones are predominant in the central retinal region (the macula); the fovea, which is the area at the 
center of the macula, contains only cones and no rods. Essentially, three types of cone opsins (or 
pigments) can be distinguished and each one is more sensitive to a certain light wavelengths: short 
(430–440 nm, red region of electromagnetic spectrum), medium (535–540 nm, green region) and long 
(560–565 nm, blue/violet region) wavelengths. The wavelength of the light perceived as the brightest 
by the human eye is 555 nm (greenish-yellow). Once a cone pigment is bleached by light, it takes about 
six minutes to regenerate. There are 120–130 million rods in each eye, and they are sensitive to dim 
light, movement, and shapes, but do not detect color. The highest concentration of rods is in the 
peripheral retina, decreasing in density up to the macula. The rod pigment is most sensitive to the light 
Polymers 2010, 2            
 
 
289 
wavelength of 500 nm. Once a rod pigment is bleached by light, it takes about 30 minutes to 
regenerate. Defective or damaged cones result in color deficiency, whereas diseased rods result in 
difficulty in seeing in the dark. Any damage to the macular region involves an acute vision loss, 
whereas damage to peripheral retina causes a loss of visual field. 
2.2.2. Vitreous Body 
The vitreous body, often referred to as vitreous humor or simply vitreous, is essentially a clear gel 
composed of water, hyaluronic acid, collagen fibrils, calcium salts and plasma proteins, and occupies 
about 75% of the eyeball volume [10–12]. The vitreous body acts as a shock-absorber element 
protecting the retina from high stresses due to sudden movements, and imparts stability to eye shape 
and maintains the retina against the Bruch‘s membrane. A residual feature of fetal vitreous synthesis is 
the Cloquet‘s canal, formed by an external shell of dense gel that surrounds a liquid core. This canal 
hosts the hyaloid artery in the fetus, which grows outward from the end of the optic nerve into the 
vitreous cavity and extends forward to the crystalline lens. Normally, the hyaloid artery regresses 
during the last trimester of fetal formation; sometimes, however, it remains after birth without having 
negative effects on vision. The Cloquet‘s canal is linked to the posterior capsule of the crystalline lens 
by the Wieger‘s ligament; a break to the canal, due to unskillful cataract surgery procedures, allows the 
liquid vitreal core to flow into the anterior chamber, thereby enhancing the tendency towards posterior 
vitreous detachment (PVD) [6,13,14]. 
3. Phenomenology of Retinal Detachment 
RD is a significant cause of blindness and, when it occurs, must be considered a serious medical 
emergency [6,15]. Typically, RD is preceded by flashes of light and/or floaters in the visual field; after 
its occurrence, the patients perceive a dark shadow interfering with vision. 
3.1. Types and Features of Retinal Detachments 
RD occurs when the retina peels away from its underlying layer of support tissue. Initial detachment 
may be localized, but without prompt treatment the entire retina may detach, thereby leading to 
progressive vision loss and subsequent blindness. Essentially, three types of RD can be distinguished: 
(i) rhegmatogeneous RD (RRD), (ii) tractional RD (TRD) and (iii) exudative (or serous) RD (ERD). 
RRD is caused by a hole, tear or break in the retina that allows vitreous fluid to pass from the vitreous 
cavity into the sub-retinal space between the sensory retina and the retinal pigment epithelium. TRD 
occurs when fibrovascular tissue, caused by trauma, inflammation or neovascularization, pulls the 
neurosensory retina away from the RPE. Finally, ERD occurs due to inflammation, injury or vascular 
abnormalities (e.g., choroid disruption) leading to fluid build-up underneath the retina without the 
presence of a hole, tear or break. 
3.2. Risk Factors 
The frequency of RD in otherwise normal eyes is about 0.005%, and mostly due to accidental ocular 
trauma or strong shocks to the head [1,6]. Some pathological conditions, however, can favor retinal 
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disorders and, in particular, RD. Severe myopia is often associated with RD cases, as extremely 
myopic eyes are longitudinally longer than normal ones and, therefore, have a more stretched and 
thinner retina. In addition, RD can occur after cataract surgery. 
TRD can occur in patients suffering from proliferative diabetic retinopathy and proliferative  
vitreo-retinopathy (PVR) [15–18]. In both retinopathies, abnormal blood vessels (neovascularization) 
grow within the retina and extend into the vitreous body; in advanced disease, the vessels can pull the 
retina away from the back wall of the eye causing TRD. TRD may occur also in children affected by 
retinopathy of prematurity. 
It cannot be ignored that eye structures undergo modifications over time; for instance, with age the 
vitreous humor changes from a gel to a liquid (vitreous liquefaction), thereby leading to PVD [13,14]. 
As this occurs, the vitreous mass gradually shrinks and collapses, separating and falling away from the 
retina; PVD, however, is a normal occurrence in people over 50. Commonly, a person having 
experienced PVD reports seeing flashing lights and/or floating bodies—commonly termed ―muscae 
volitantes‖ (flying flies)—in his or her field of vision. These flashes of light occur when the vitreous 
tugs on the sensory layer of the retina. The floaters, which are cells or debris released during vitreous 
detachment, can appear as little dots, circles, lines, clouds or puffs of smoke. Although PVD is a 
natural age-related phenomenon, it may occur earlier than normal in extremely myopic people, being 
favored by the over-elongation of the longitudinal axis of the eyeball. Usually, the vitreous makes a 
clean break as it pulls away from the retina; sometimes, however, the vitreous may adhere tightly onto 
certain retinal regions creating traction points; hence, horseshoe-shaped rips in the retina can result 
from persistent tugging and tearing by the vitreous [5,6]. Unless the retinal tear is repaired, fluid can 
seep through this hole underneath the retina causing RRD.  
4. Treatment of Retinal Detachment 
The general schedule adopted for RD treatment comprises three fundamental steps: the surgeon 
must (i) detect all retinal tears, (ii) seal all retinal breaks and (iii) relieve vitreoretinal tractions. 
Depending on the patient‘s clinical condition and, specifically, on the features of retinal breaks, 
different approaches can be proposed [3,4,6,15,19,20]. Laser therapy is suitable if no separation of 
retinal tissues or very small RRD occurred, whereas extensive RD requires surgical treatments to 
reattach the neural retina to the RPE. RRDs are generally treated by employing either pneumatic 
retinopexy or scleral buckling, both in conjunction with retinal cryopexy/laser photocoagulation. The 
repair of TRDs or particularly complicated cases, involving for instance multiple retinal breaks or giant 
tears, also require the substitution of the vitreous with a tamponade agent (vitrectomy). A short 
overview of these procedures is given in the following sections.  
4.1. Laser Retinopexy 
When a small retinal tear occurs, laser treatment may be applied to prevent further accumulation of 
fluid beneath the retina, thereby minimizing the risk of extensive vision-threatening RDs. The laser is 
applied around the retinal hole and, over the course of a few weeks, the treated area develops a scar 
which forms a tight seal between the retina and the underlying tissue. This procedure is sometimes 
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performed around weak retinal areas in patients who may be at higher risk for RD. Laser retinopexy 
(endophotocoagulation) can be performed in conjunction with pneumatic retinopexy, scleral buckling 
and vitrectomy. 
In addition, laser therapies are often used to prevent a potential RD. When abnormal retinal blood 
vessel growth occurs in diseases such as proliferative diabetic retinopathy or retinal vein occlusion, 
laser must be applied to large areas of the peripheral retina that, having poor blood flow (ischemia), are 
responsible for releasing growth factors causing neovascularization. If untreated, retinal 
neovascularization often leads to vitreal hemorrhage, neovascular glaucoma and/or TRD. After laser 
therapy is applied, the blood vessels tend to stabilize or regress. 
4.2. Retinal Cryopexy 
The final result of cryotherapy is similar to that obtained by laser retinopexy: in fact, cryopexy 
stimulates scar formation allowing the edges of a retinal tear to seal. This is typically done by looking 
into the eye using an indirect ophthalmoscope, while pushing gently on the outside of the eye using the 
cryopexy probe. The probe produces a small frozen area that includes the retina and the tissues 
immediately underneath it, thereby sealing the retinal tear. Cryopexy is used for treating large breaks 
and in areas that may be hard to reach by laser; it can be used in conjunction with pneumatic 
retinopexy, scleral buckling and vitrectomy. 
4.3. Pneumatic Retinopexy 
Pneumatic retinopexy involves the injection of an expansive gas into the eye posterior chamber to 
flatten the retina, thereby allowing the sub-retinal fluid to be pumped out from beneath it. The patient‘s 
head is properly positioned so that the gas bubble floats to the detached area and presses against the 
detachment. A freezing probe (cryopexy) or laser beam (photocoagulation) can be used to seal the 
retinal tear. The gas bubble is gradually absorbed by the eye while a seal forms between the retina and 
the underlying tissue. 
4.4. Scleral Buckling 
After laser photocoagulation or cryopexy has been performed to seal retinal tears, a scleral buckle 
may be indented on the sclera (Figure 2). The buckle closes the tear and reduces the eyeball volume, 
thereby preventing further pulling and separation of the vitreous from the retinal layer. Depending on 
the RD severity, a buckle may be local (segmental buckle is often called ―plombage‖) or placed around 
the entire eyeball (equatorial encircling band, as shown in Figure 2). Afterwards, the subretinal fluid, 
which could interfere with the retina reattachment, is usually drained and the buckle is sutured to the 
sclera to hold it in place. An inevitable side effect of scleral buckling procedures is myopic shift [21]. 
Usually, the buckle remains in place for the patient‘s lifetime and it does not interfere with vision. 
Temporary buckles can alternatively be chosen, for instance in children to allow eyeball growth, but 
they need to be surgically removed later. 
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Figure 2. Scheme of scleral buckling for treating retinal detachment. 
 
4.5. Vitrectomy 
Vitrectomy involves the partial or total removal of vitreous humor and its temporary substitution 
with a gaseous (rarely) or liquid tamponade agent; semisolid or gelatinous vitreous substitutes have 
also been experimentally tested. This procedure is necessary to clear blood and debris from the eye, to 
remove scar tissue and to eliminate tractions on the retina. Blood and debris, such as due to vitreous 
hemorrhage, obscure light as it passes through the eye, thereby resulting in blurred vision. In addition, 
in some cases of RD, the surgeon‘s view of the damage might be hindered by bleeding inside the eye 
and, therefore, vitrectomy in conjunction with scleral buckling must be performed. Vitrectomy is 
typically performed in treating TRD, as in this case the vitreous pulls away and tugs the retina from its 
normal position. 
5. Materials for Pneumatic Retinopexy 
The procedure of pneumatic retinopexy is commonly considered a good surgical option for treating 
uncomplicated RRDs with a 90% success rate, but often repeated operations are necessary. Table 1 
summarizes and compares the advantages and disadvantages of gases used in pneumatic retinopexy 
procedures. 
The first procedure of pneumatic retinopexy was attempted in 1911 by Ohm [22], who injected 
purified air into the vitreous cavity to adhere the retina to the inner wall of the eye. Air, however, 
cannot be used as a long-term vitreous substitute, as its intravitreal residence time only lasts a few days 
[4]. In recent years, air has only occasionally been used in pneumatic retinopexy procedures [23,24]. It 
has been used in conjunction with other vitreous tamponade agents during vitrectomy procedures, but 
some evidences suggested that its use is unhelpful [6,25]. Furthermore, air can be used in the course of 
the so-called D-ACE procedure (Drain, Air, Cryotherapy, Explant) [26]. 
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Table 1. Gases used in the course of pneumatic retinopexy procedures. 
Gas Advantages Drawbacks References 
Air Absence of toxicity. 
Short persistence time in the 
vitreous cavity (<5 days). Partial 
retinal reattachment. 
[4,22–26] 
SF6 
Absence of toxicity. Retinal 
reattachment approximately 
>90% (today).  
Transient IOP rise (from moderate 
to high). Glaucoma. Cataract. 
[27,31,32, 
191,192] 
SF6/air blends Analogous to SF6 alone. Analogous to SF6 alone. [33] 
Perfluorocarbon 
gases (PFCGs) 
Absence of toxicity. Retinal 
reattachment approximately 
>90% (today). 
Transient IOP rise (from slight to 
moderate). Cataract. 
[28–30, 
191,192] 
PFCG/air 
blends 
Analogous to PFCG alone. Analogous to PFCG alone. [34] 
Xenon 
Absence of toxicity. 100% 
retinal reattachment. 
Very short persistence time in the 
vitreous cavity (<1 day). 
[35,36] 
Rare gases 
(argon, helium), 
CO2, N2O. 
Absence of toxicity. 
Short persistence time in the 
vitreous cavity (comparable to air). 
[35] 
In the early 1970s, Norton used sulfur hexafluoride (SF6) for pneumatic retinopexy and found the 
persistence of gas and its expansive features superior to air [27]. In 1980 Lincoff et al. [28] proposed 
the use of perfluorocarbon gases (PFCGs), i.e., C2F6, C3F8, C4F8 and C5F12; their advantages over SF6 
include a lower requirement of intravitreal injected volumes due to increased expansion and longer 
persistence thanks to their low solubility [29]. Thus, the use of PFCGs may result in a lower rise in 
initial IOP than that evaluated with SF6 (acute glaucoma) because of the smaller injected volume. In 
addition, their increased persistence (approximately one week versus 3–4 days) allows prolonged 
tamponade, thereby promoting the formation of secure chorioretinal adhesions. Major drawbacks of 
such gases are the need for patient‘s post-operative posturing to exert the maximum tamponade effect 
and the persistence of quite high IOP values that can result in damage to the optic nerve. In addition, 
cataract formation and damage to ciliary body and retina, especially due to the use of C3F8, may  
occur [30]. SF6 and PFCGs have been also experimented with for vitrectomy procedures [31,32], but 
other vitreous substitutes have been found more suitable for such surgery, as will be described later. 
Blends of SF6/air or PFCG/air (with air content <30%vol.) were also used with similar success rates 
to those obtained by using solely SF6 or PFCGs [33,34]. 
Lincoff et al. tested a wide series of gases in an animal model, including argon, helium, xenon, N2O 
and CO2, to measure disappearance times [35]. Xenon was also tested in four human patients with 
excellent clinical outcomes (100% retinal reattachment) [36]. Generally these gases disappeared very 
rapidly (for instance, in the case of xenon, almost 90% in 3 hours postoperatively) and it was necessary 
to replace them with aqueous solution; this two-step operative procedure has been abandoned and, at 
present, SF6 or PFCGs are the gases of choice for surgeons.  
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6. Materials for Scleral Buckling 
In 1937, Jess performed what may be considered the first scleral buckling by using a gauze pad to 
temporarily indent the eye wall for approximating the retinal layer with the choroid [37]. The implant 
was removed after a few weeks and no ocular tissue reactions were reported. Since then, several 
materials and design styles have been proposed for manufacturing scleral implants. Basically, scleral 
buckles may be categorized in two classes: (i) permanent implants and (ii) absorbable devices. 
Materials tested over the years for manufacturing buckles are listed in Table 2 and Table 3. At present, 
only silicone implants are commercialized and routinely used in clinical practice, and all other non-
absorbable devices have progressively fallen into disuse.  
Degradable implants in general carry a higher number of problems and less advantages in 
comparison with permanent ones, and until now all have only been tested experimentally. 
6.1. Permanent Buckles 
6.1.1. Implants Fallen in Disuse: Historical Overview 
Table 2 qualitatively summarizes the complications encountered using different buckling materials 
proposed in the literature over the years, but have fallen into disuse; silicone is not included here as it 
will be treated separately in the next section. 
Almost 20 years after the procedure reported by Jess [37], Custodis tested a polyviol band as a 
scleral buckling element [38,39]. After compression over sclera, the implant could expand in situ 
postoperatively, thereby allowing the closure of retinal breaks and the retina reattachment. However, 
polyviol elicited serious adverse reactions in the ocular tissues was thus not considered suitable for 
clinical use.  
Table 2. Scleral buckling materials having progressively fallen into disuse (chronological order). 
Material 
Long-term Complications 
a
 
References 
b
 Scleral 
Erosion 
IOP 
Increase 
Adverse 
Tissue 
Response 
Friability 
Migration, 
Extrusion 
Foreign 
Body 
Sensation 
Persistent 
Pain 
Polyviol  +++ +++     [38,39] 
Polyethylene +++ +++      [40–42] 
Nylon 
threads 
+++  +     [44,45] 
Solid PTFE ++ ++ +     [46–48] 
Polyester ++  +     [49,50] 
Hydrogels    +++ + + + [51–59] 
Porous PTFE + + ++   + + [60–64] 
PTFE-coated 
silicone 
+ + ++   + + [65–67] 
a
 Legend: ‗+‘ = rare/negligible problem; ‗++‘ = occasional/mild problem; ‗+++‘ = serious problem. 
b
 Citation numbers are referred to in the main text. 
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In response to the failure of polyviol, in the mid 1950s Schepens proposed polyethylene (PE) tubes 
as encircling scleral elements: PE could be easily manufactured to produce buckles of different 
diameters, that could easily be tensioned in situ by means of a suture placed in the tubing  
lumen [40,41]. However, Regan reported that the hardness and rigidity of PE tubes exerted too severe a 
pressure on the ocular globe and, furthermore, the narrow bearing surface of tubes eventually caused 
erosion of the underlying sclera and choroid [42]. 
In order to overcome the drawbacks related to PE tubes, in the late 1950s the use of silicone 
elements was proposed for the first time by Girard et al. [43]; this material remains the best choice 
today and is described in the next section. 
As an alternative to PE, in 1958 nylon braided threads were also proposed for scleral buckling [44]: 
they were not properly used as a ―buckle‖ but rather for suturing the wall of the eye to create a ―fold‖ 
which then created a buckling effect. This solution was soon abandoned due to scleral inflammation 
and erosion [44,45]. 
Solid polytetrafluoroethylene (PTFE) was tested in the mid 1960s by Wolter et al. [46,47], but 
Deodati et al. showed that Teflon implants exhibited similar complications to those encountered with 
PE tubes [48]. Analogous problems were also encountered by using polyester bands as cerclage 
elements in the early 1970s [49,50]. 
A particular mention should be made to hydrogel implants, as they were considered superior to 
silicone implants for almost 20 years (from their introduction in the mid 1970s to their progressive 
abandonment in the 1990s), especially as they were softer and seemed to carry a lower risk of infection 
(less than 1% vs. 2–5%) [51,52]. Specifically, three types of hydrogels, i.e., poly(glyceryl methacrylate) 
(PGMA), poly(2-hydroxyethyl acrylate) (PHEA), and poly[methyl acrylate-co-(2-hydroxyethyl 
acrylate)] (MAI), have been widely investigated [53]. Major advantages of hydrogels are softness, 
defined swelling under hydration and the potential to act as devices for the controlled release of 
hydrophilic drugs [54], which is an advantage over solid silicone implants in controlling infection. 
PGMA was found to suffer from lack of tensile strength when swollen, whereas PHEA exhibits a 
dramatic tendency to fragment after swelling [55]. MAI, which is commercially sold as Miragel, offers 
better bulk features and can promote the formation of a strong surrounding  
capsule [53,54]. Although Miragel has been considered by many surgeons as the ideal solution for 
scleral buckling, fragmentation of such implants can occur after 10-year follow-up [55–58], as well as 
buckle overexpansion [56,59], with an associated risk of severe long-term complications (persistent 
pain, foreign body sensation) and the need of re-operation for implant removal. 
Porous expanded PTFE (e-PTFE) was proposed in the form of buckling bands [60–64] or, more 
recently, as coating on silicone implants [65–67] with variable and controversial outcomes. Potentially, 
the material could be an alternative to silicone, but further studies of its performances and effects in 
vivo are necessary.  
For the purpose of completeness, it is interesting to mention an approach attempted in 1977 by 
Gloor, who used a silver clasp as an episcleral buckle [68]. The implant was removed after six months 
due to the pain experienced by patients and to avoid severe eyeball deformations. It should be 
underlined that, apart from the cotton gauze used by Jess in 1937, this is the only other case involving 
the use of non-polymeric materials for scleral buckling.  
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6.1.2. Routinely Used Implants in Clinical Practice 
At present, silicone is commonly considered the material of choice in scleral buckling procedures 
and a wide range of silicone implant styles (over 70) are commercially available for ophthalmic 
surgeons worldwide. Silicone is a synthetic rubber compound, hydrophobic and highly stable within a 
wide temperature range. The first silicone scleral buckle, employed by Girard et al. in 1959, was a 
simple rod-shaped element [43]; since then, more than 70 silicone-based implant designs have been 
developed by surgeons. It has been extensively demonstrated that silicone implants are economical, 
soft, biochemically inert, non-allergenic and generally well-tolerated by the body. 
In vivo they remain soft and flexible, thereby avoiding scleral erosion as shown by PE  
implants [42]. It is interesting to underline that the changes in silicone implant design have been 
―evolutionary‖ rather than ―revolutionary‖: in fact, many surgeons have contributed their design inputs 
and have built on the success of their predecessors to achieve new design ideas, and each silicone 
element has been carefully thought out and developed to meet a specific need, e.g., short surgery time, 
low cost, indentation depth.  
The smoothness of silicone material and the implant rounded contour lead to the development of a 
tough, collagenous capsule around the implant [69]; at first vascularized, the capsule eventually 
becomes avascular and translucent over time. In episcleral implants the capsule seals off the buckle, 
thereby helping to minimize the risk of later infection. As regards intrascleral implants, the capsule 
also grows between the implant and sclera, thereby giving further protection against scleral  
erosion [70]. Because dense silicone does not allow tissue in-growth, the implant can easily be taken 
out in one piece without too much trauma, if removal becomes necessary [71,72].  
Silicone sponge buckles, introduced by Lincoff et al. for treating large retinal tears [73] are 
closed-cell foams which have the same chemical composition as solid silicone implants. With respect 
to dense implants, silicone sponges are designed to be more elastic and to produce a more even 
buckling effect, which usually increases postoperatively [74]; in addition, the sponges can be 
impregnated with antibiotics to limit the bacterial colonization of the implant [75]. In most cases 
silicone sponges are used as episcleral implants, but they can also be placed under scleral flaps  
if desired. 
Although silicone implants are generally considered as ―the gold standard‖ solution for scleral 
buckling, and rightly so they can occasionally induce some or even all the long-term complications 
listed in Table 2, as underlined by recent studies [76,77]. 
6.2. Absorbable Implants 
Degradable buckles have been experimented with to overcome the long-term problems related to 
permanent implants (Table 2), as they are replaced by scar tissue in the normal course of tissue 
turnover; this process normally takes from a few weeks to a year or more postoperatively depending on 
the degradation rate of the chosen material. At present, no absorbable buckles are commercially 
available, and they have only been used as experimental implants. 
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The major problem with absorbable buckles relates to the ability to retain the buckling effect over 
time, as the duration of their scleral indentation must be sufficient to allow complete retinal 
reattachment (anatomic success of the operation). 
A wide range of absorbable materials of biological or synthetic origin were tested to achieve a 
temporary buckling effect; Table 3 gives a qualitative overview of the suitability of different 
absorbable buckles tested over the years. Biological materials were derived from human or animal 
tissues, and they were used to perform transplants (autografts, allografts and xenografts) or properly 
treated to obtain suitable substances, e.g., gelatin or fibrin. Autologous tissues, e.g., patient‘s  
tendons [78] or fascia lata tensor muscle [79–81], were proposed to avoid rejection, but such implants 
require extra-surgery procedures for graft harvesting. Allografts from cadavers, e.g., freeze-dried 
samples of sclera [82–85], skin [86,87], dura mater [88] or pericardial tissue [89], have been 
experimented in the past, but they carried the risk of host rejection and diseases transmission from the 
donor to the patient; therefore, there has only been occasional experimental use of allografts in the last 
decade [89]. In addition, allografts exhibited generally low elasticity, which limits the ability of 
accurately tailoring buckles‘ size and shape. Gelatin sheets derived from pig skin or bone xenografts 
were widely tested as buckling elements by Schepens and co-workers [90–92] and other  
groups [93–97], but such grafts revealed problems analogous to those carried by allografts. Fibrin rods 
were also tested by Grosz et al. [98] and Wollensak et al. [99] with bad clinical results, as the retina 
remained partially detached postoperatively due to the short duration of scleral indentation (<1 month). 
Table 3. Scleral buckling using absorbable implants. 
Material Adverse Tissue 
Response 
a
 
Persistence of 
Indentation 
b
 
References 
c
 
Origin Type 
Biological 
Surgical gut +/++ ●/●● [100–104] 
Gelatin +/++ ●● [90–97] 
Tendon + ●● [78] 
Fascia lata + ●● [79–81] 
Sclera + ●● [82–85] 
Fibrin + ● [98,99] 
Skin +/++ ●● [86,87] 
Dura mater + ●● [88] 
Pericardial patches + ●● [89] 
Synthetic 
PGA + ● [97,108,109] 
PGA/PLA + ●● [97,108,109,113] 
PDO + ●● [97,114,115] 
PU +/++ ●●● [116,117] 
PLA + ●●● [110–112] 
a
 Legend: ‗+‘ = rare/negligible/found in the very early postoperative period; ‗++‘ = 
occasional/mild/found in the early postoperative period; ‗+++‘ = serious/persistent. 
b
 ‗●‘ = too short (< 1 month); ‗●●‘ = generally sufficient for retinal reattachment; ‗●●●‘ = long  
(>1 year). 
c
 Refer to the main text for citation numbering. 
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An interesting approach was attempted in dogs by Dellaporta, who used surgical gut sutures as 
encircling elements placed within scleral folds to create a temporary indentation [100]. However, after 
a series of experiments [100–104], this solution was abandoned as the operative technique could 
involve clinical complications (inflammation of choroid and ciliary body) and the duration of the 
buckling effect was highly variable (the indentation was found to persist from one week up to  
five months). 
Temporary buckles involving the injection of air [105], autologous fat [106] and hyaluronic  
acid [107] into the suprachoroidal space were also occasionally attempted; however, this approach was 
soon abandoned as the surgical procedures could lead to choroid perforation and haemorrhage; the 
control of buckle size and shape was very poor; and the buckling effect was limited to a few days.  
In order to overcome the problems related to biologically-derived absorbable buckles, some 
synthetic polymers were proposed in the last three decades for manufacturing buckling elements; 
specifically, five materials were tested in vivo: poly(glycolic acid) (PGA) [97,108,109], poly(lactic 
acid) (PLA) [110–112], PGA/PLA composites [97,108,109,113], polydioxanone (PDO) [97,114,115] 
and polyurethane (PU) [116,117]. In general, they exhibited some advantages in comparison with 
biological materials; eliciting minimal or no adverse reactions; offering controllable and predictable 
absorption kinetics; and being easily shapeable to obtain an implant of desired size and design. Until 
now, all these polymers were used only experimentally in a limited number of cases (rabbits or 
humans) and the reports of research are still incomplete. As preliminary results are very promising 
(especially for PLA [110–112] and PU [116,117] buckles), further systematic experimentation is 
warranted to investigate their actual suitability for clinical use in humans. 
7. Materials for Vitrectomy 
Gases are unsatisfactory as long-term tamponade agents because of their short residence time in the 
vitreous cavity; for this reason, liquids or gelatinous solids, that can respond to head movements 
maintaining a tamponade effect, should be used in the case of prolonged vitreous substitution. In the 
course of surgical procedures aiming to treat RD, vitreous substitution may also be combined with 
scleral buckling. 
As outlined by Chirila and co-workers in two fundamental works [118,119], an ideal vitreous 
substitute should be (i) non-toxic and biocompatible with ocular tissues, (ii) clear and transparent with 
refractive index and density similar to those of natural vitreous, (iii) biologically and chemically inert, 
(iv) sufficiently rigid to act as an effective tamponade agent, (v) able to allow the transfer of 
metabolites and proteins, (vi) preferably non-absorbable and non-biodegradable in order to be 
maintained in the vitreous cavity for as long as possible, (vii) preferably hydrophilic and insoluble in 
water, (viii) injectable through a small-gauge needle, (ix) able to maintain its properties after injection, 
(x) storable and sterilizable without losing the above-mentioned properties.  
At present, such materials able to fulfill this set of requisites do not exist, which makes research for 
an ideal vitreous substitute more and more stimulating and challenging. 
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7.1. Routinely Used Vitreous Substitutes 
7.1.1. Silicone Oils 
Since the 1960s, different types of silicone oils (SiOs) have been widely used in the management of 
complicated forms of RD requiring vitrectomy; such as cases complicated by PVR or proliferative 
diabetic retinopathy [15,16]; giant retinal tears/vitreal tractions (TRD) [120,121]; or inferior  
RRD [122]. The use of SiOs as a vitreous substitute for treating RD cases was extensively reviewed by 
Giordano et al. in a fundamental treatise [123], to which the interested reader is referred for  
more details.  
SiOs belong to the class of polydimethylsiloxanes and exhibit excellent stability and transparency; 
their main physical features are reported in Table 4. The hydrophobic nature of SiOs emphasizes its 
tamponade effect, thereby ensuring the closure of retinal holes and reducing sub-retinal leakage; the oil 
resides in the vitreous cavity until it is surgically removed. When the silicone liquid is injected into an 
aphakic or pseudophakic eye, the oil has access to the anterior chamber and corneal complications may 
occur, probably because access to nutrients is blocked [124]. Other problems such as angle-closure or 
pupillary-block glaucoma, inflammation and keratopathy may also be associated with SiOs [121,123]. 
In order to reduce the risk of pupillary-block glaucoma and to keep the anterior chamber free of 
silicone in aphakic eye, it is necessary to avoid overfilling and, in addition, inferior peripheral 
iridectomy can be helpful to allow the silicone globules to return to the vitreous cavity when the patient 
is in the prone position [125]. Cataract may eventually develop in phakic eyes because of blocked 
nutrient diffusion across the posterior lens capsule (incidence usually within 6–18 months after 
surgery) [126,127]. The low density of SiOs (Table 4) causes it to float upon the residual vitreous fluid, 
which involves a reduced tamponade effect in the case of inferior retinal breaks. In such a situation, 
placing the patient in the prone position is required. It was demonstrated that  
residual components of polymerization reactions can diffuse into the retina, thereby causing acute  
cytotoxity [128]. The tendency towards oil dispersion and emulsification is the major problem, as cells 
containing silicone vesicles revealed alteration in their metabolic activities [129]. Emulsification can 
be successfully reduced by using high-viscosity (>4000 cSt) oils [121,123,129]. 
Fluorosiicone oil (FSiO) has physical properties similar to those of SiOs, but exhibits a higher 
emulsification rate and lower intraocular tolerance [123]. FSiO and silicone/fluorosilicone copolymer 
oil can be useful as intraoperative tools and short-term tamponade agents (<2 months), but they are not 
recommended for prolonged retinal tamponade due to possible complications, including cataract, 
glaucoma, uveitis and keratopathy. 
7.1.2. Perfluorocarbon Liquids 
Perfluorocarbons with more than five carbon atoms in their molecule are liquid at room 
temperature; their main physical properties (at 20 °C) are reported in Table 4. Perfluorocarbon liquids 
(PFCLs) for ophthalmic use have been reviewed in detail elsewhere [130]. The higher density of 
PFCLs in comparison to that of SiOs also allows tamponade of inferior retinal breaks; this feature, 
together with high transparency, low viscosity and inert behavior, would seem to make PFCLs 
excellent material for long-term vitreous substitutions [128,130]. In addition, recent studies 
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demonstrate that they can be successfully used instead of silicone oil, also in RD cases complicated by 
PVR [131]. However, it cannot be ignored that their persistence over more than four days 
postoperatively leads to severe complications. In general, the drawbacks related to PFCLs seem to be 
due to their high density, resulting in mechanical damage to cells through compression and extensive 
emulsification, rather than to an intrinsic material toxicity [130]. Reported problems include secondary 
glaucoma from retained intraocular PFCL, as well as central scotomas from retained subfoveal  
PFCL [132,133]. Toxicity to the RPE and photoreceptors was demonstrated in an animal model with 
retained subretinal PFCL [134]; other research demonstrated stromal inflammation, loss of endothelial 
cells and corneal vascularization in aphakic rabbit eyes that were injected with PFCLs [135]. The 
presence of intravitreal PFCL in rabbits has been shown to cause retinal atrophy with severe thinning 
of the outer plexiform layer and damage to photoreceptors. Risk factors for retained subretinal PFCL 
include large peripheral retinotomies greater than 120°, as well as lack of a rinse by saline solution 
after PFCL removal [136].  
Table 4. Typical physical properties of the routinely used vitreous substitutes compared 
with human vitreous. 
Material RI Density (g/cm
3
) Mw (Da) Viscosity (cSt) References 
Silicon oil 1.380–1.404 0.97–0.98 40000–80000 1000–10000 [120,123,128] 
Perfluorocarbon 
liquids 
1.20–1.40 1.5–3.0 350–1000 2–5 [128,130] 
Human vitreous 
humor 
1.3345–1.3348 1.0053–1.0089 5000000 4–5 [10–12] 
7.2. Experimental Vitreous Substitutes 
At present, PFCLs are commonly used as short-term substitutes during intraoperative procedures, 
whereas the preferred agent for prolonged vitreous tamponade remains SiOs. The search for an ideal 
vitreous substitute, able to actually mimic the features of natural vitreous, is currently in progress; 
Table 5 summarizes the features of the experimental vitreous substitutes proposed in the literature  
to date.  
It is worth mentioning that the first selection criterion for a material is its optical properties, as a 
potential vitreous substitute must primarily be clear and transparent to the light. Besides the optical 
suitability, other properties should be taken into account to evaluate if a specific polymer is a good 
candidate for vitreous substitution: in this context, the main advantages and drawbacks of the materials 
listed in Table 5 will be discussed and compared in the following subsections. If available in the 
literature, quantitative assessment of physical properties of potential vitreous substitutes will also  
be reported. 
7.2.1. Natural Materials 
Chronologically, healthy animal donor vitreous was the first material used for vitreous replacement 
at the beginning of the 20th century, when Deutschmann injected calf and rabbit fresh vitreous into 
human patients‘ eyes [137]. Then, human donor vitreous [138,139], or water and physiological 
solutions [140–142], were also used. No relevant differences in the clinical outcomes were found 
Polymers 2010, 2            
 
 
301 
between using physiological solutions or donor vitreous. There is a great variability in the reported 
performances of such agents: in many cases, they were found suitable for the immediate treatment of 
RD cases, but they failed in the long-term due to postoperative complications, e.g., inflammation of the 
ocular tissue, cataract, corneal damage, glaucoma and various retinopathies; in addition, their short 
residence time in the vitreous cavity often did not allow the prolonged flattening of the retina to 
achieve its complete reattachment.  
At present, water-based balanced salt solutions are used only for intravitreal washes in the course of 
vitreoretinal surgery procedures or after removing other vitreous substitutes such as SiOs [143].  
In order to overcome the above-mentioned drawbacks, research progressively moved towards 
semisynthetic polymers, i.e., modified natural polymers.  
7.2.2. Semisynthetic Polymers 
As shown in Table 5, the failure of semisynthetic polymers as effective vitreous substitutes was 
mainly due to them lacking a mid/long-term tamponade effect. This was essentially attributable to their 
rapid bioabsorption and/or biodegradation in vivo; in addition, their physical and mechanical properties 
were generally poorer than those of natural vitreous.  
Collagen 
Proctase-treated collagen gel was the first semisynthetic polymer used for vitreous substitution; the 
choice of collagen seemed reasonable as it is one of the two major components of natural vitreous. 
Preliminary studies in rabbits by Stenzel et al. [144] and in monkeys by Dunn et al. [145] showed that 
the material was generally well tolerated by ocular tissues with mild transient inflammation.  
In the early 1970s, collagen gels were tested in humans by Pruett et al. [146,147]: a moderate 
inflammation of ocular tissues was reported, together with other severe complications related to 
clinical outcomes; in fact, only 19% of the cases exhibited retinal reattachment and all patients 
recovered only partial vision, due to vitreous opacification causing blurred vision in the patients. In 
addition the gel underwent fragmentation during injection, thereby decreasing its mechanical properties. 
More recently, the use of methylated type I/III collagen overcame some of these drawbacks [148,149]: 
in fact, after implantation in rabbits, no inflammation and no vitreous/lens/cornea opacification were 
detected. However, the poor surface tension for tamponading effect made this polymer unsuitable for 
RD treatment. 
Gelatins 
Polygeline, a modified gelatin (RI = 1.3390, Mw = 35 kDa), was implanted in both rabbits [150] and 
humans [151]. The material was generally well-tolerated without adverse tissue reactions and the 
immediate retinal reattachment was successful in most patients. However, polygeline exhibits a short 
retention time in the vitreous cavity and a rapid decrease of its viscosity. Attempts to increase the 
viscosity by adding gelatin, agar, methylcellulose and poly(ethylene glycol) caused inflammation and 
cloudiness in the vitreous. Therefore, polygeline could be useful only as a short/mid-term vitreous 
substitute. However, due to its good biocompatibility and excellent optical properties, the material 
justifies further investigations. 
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Very recently, Lai investigated the ocular biocompatibility of two chemically modified gelatin 
hydrogels [152]. The material was not specifically proposed as a vitreous substitute—gelatin was 
injected in the anterior chamber of rabbit eyes and its use as a controlled drug delivery agent was 
suggested—but this could be warranted after further studies. The gelatin was cross-linked with 
glutaraldheyde (GTA) or 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimide (EDAC); a significant 
inflammatory reaction was elicited by the presence of GTA-treated material, whereas EDAC-cross-
linked gelatin hydrogel exhibited good biocompatibility and was well-tolerated without causing 
toxicity or other adverse effects. No other studies on such materials are available in the literature, but 
the results obtained for EDAC-treated gelatin makes this hydrogel worthy of further investigations. 
Sodium Hyaluronate and Other Polysaccharides 
Sodium hyaluronidate has been extensively tested as a vitreous substitute in humans since the  
early 1960s [153]. Like collagen, its use was considered since this biopolymer is present in natural 
vitreous. Sodium hyaluronidate is commercially available in a wide range of pharmaceutical grade 
solutions, and it showed an excellent biocompatibility and tolerance in ocular tissues. However, these 
solutions were not suitable for vitreous substitution due to their short residence time in the vitreous 
cavity and their poor tamponade effect [154]. Recently, longer residence times were observed after 
cross-linking sodium hyaluronate with divinyl sulfone or formaldehyde, but some problems still 
remained [155]. 
It is worth giving a special mention to the so-called ―reconstituted vitreous‖, a mixture of sodium 
hyaluronidate and collagen that are the two major structural components of the vitreous body [156]. 
The basic idea was fascinating, as the researchers‘ aim was to mimic nature by duplicating both the 
composition and the structure of the natural vitreous. After injection at low temperature (~10 °C) the 
mixture can undergo gelification in situ at body temperature. However, in vivo studies revealed 
problems of gel hazing during postoperative follow-up and, occasionally, ocular tissue inflammation; 
in addition, the material was completely bioabsorbed within five months. 
Occasionally, various solutions of different polysaccharides, e.g., dextrin, alginic acid and 
chondroitin sulfate, was tested as vitreous substitutes in rabbits and humans [157,158]; generally, no or 
slight inflammation was reported, but the vitreous underwent opacification and often the material 
failed to reattach the retina. 
Gellan Gum/Hyaluronic Acid Gel 
Recently, Suri et al. mixed gellan gum with hyaluronic acid and proposed it as a short-term vitreous 
substitute [159]. Gellan gum forms a gel at room temperature and the gel structure is maintained also at 
body temperature. Preliminary in vitro tests carried out by using mouse fibroblast cells showed an 
excellent biocompatibility (cells viability >90%). However, the rheological and mechanical properties 
seem to be dramatically insufficient compared to those of natural vitreous. The mechanical properties 
can be improved by adding CaCl2 to the gellan gum/HA mixture in order to obtain a highly 
cross-linked hydrogel. Further in vivo studies are undoubtedly necessary to evaluate the properties and 
performance of this promising material in detail. 
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Table 5. Features of experimental polymeric vitreous substitutes. 
Material 
Recipient Transparent
b
 Hydrophilic
b
 
Non-
absorbable/ 
non-
degradable
b
 
Mechanical 
similarity to 
natural 
vitreous
b
 
In situ 
gelification
b
 
Non-traumatic 
implantation
b
 
Injectable 
without 
degradation
b
 
No mid/long-
term clinical 
complications
b
 
References
c
 
Origin/class Type 
a
 
Natural 
Animal 
vitreous 
Human + + × + × + + × [137] 
Human vitreous Human + + × + × + + × [138,139] 
Water and 
physiological 
solutions 
Human + + × × × + + × [140–143] 
Semisynthetic 
polymers 
Proctase-
treated collagen 
Rabbit, 
monkey, 
human 
+ + × + × + × × [144–147] 
Methylated 
collagen 
Rabbit + + × + × + + + [148,149] 
Polygeline 
Rabbit, 
human 
+ + × + × + + + [150,151] 
Sodium 
hyaluronate 
Human + + × × × + + + [153–155] 
Sodium 
hyaluronate + 
collagen 
Monkey + + × + + + + + [156] 
Gellane gum + 
hyaluronic acid 
In vitro 
tests only 
+ + × × + + + − [159] 
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Table 5. Cont. 
Material 
Recipient Transparent
b
 Hydrophilic
b
 
Non-
absorbable/ 
non-
degradable
b
 
Mechanical 
similarity to 
natural 
vitreous
b
 
In situ 
gelification
b
 
Non-traumatic 
implantation
b
 
Injectable 
without 
degradation
b
 
No mid/long-
term clinical 
complications
b
 
References
c
 
Origin/class Type 
a
 
Synthetic 
polymers 
PVP 
Rabbit, 
human 
+ + × + × + × + [160–164] 
VP/HEMA 
copolymer 
Rabbit + + × + × × × × [165] 
PAA Rabbit + + + + + + + × [166–172] 
PGMA Rabbit + + + − × + × + [173,174] 
PHEA Rabbit + + − − + + + × [143] 
PHEMA Rabbit + + + − × × × + [175] 
Silicone gel Monkey + × + − + + + + [176] 
HPMC Rabbit + + × × × + + + [177,178] 
Pluronic F127 Rabbit + + × + × + × × [179–181] 
PMAGME Rabbit + + + + × + + × [182] 
PVA 
Rabbit, 
monkey 
+ + × + × + + + [183–185] 
PVA-MA 
In vitro 
tests only 
+ + × × + + + − [186] 
Adcon-L 
hydrogel 
Rabbit + + × − × + + × [187] 
SFAs Human + × + − × + + + [188–190] 
a
 Acronyms: PVP = poly(1-vinyl-2-pyrrolidone); VP = 1-vinyl-2-pyrrolidone; HEMA = 2-hydroxyethyl methacrylate; PAA = polyacrylamide; PGMA = poly(glyceryl 
methacrylate); PHEA = poly(2-hydroxyethyl acrylate); PHEMA = poly(2-hydroxyethyl methacrylate); HPMC = hydroxypropyl methylcellulose; PMAGME = poly(methyl 
2-acrylamidoglycolate methyl ether); PVA = poly(vinyl alcohol); PVA-MA = poly(vinyl alcohol methacrylate); SFAs = semifluorinated alkanes. 
b
 Legend: ‗+‘ = the material exhibits the property; ‗×‘ = the material does not exhibit the property; ‗−‘ = data not assessed/not available in the literature. 
c
 References refer to numbering in the main text. 
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7.2.3. Synthetic Polymers 
In general, problems encountered by using semisynthetic polymers taught the following lesson: ―It is 
impossible, at present, to duplicate nature and find a material able to simultaneously reproduce the 
structure, composition and performance of natural vitreous humor‖. Therefore, the ―fil rouge‖ of 
current research has been progressively addressed to find/synthesize highly biocompatible polymers 
able to duplicate the functional properties of natural vitreous, rather than its structural ones.  
It is worth underlining that also SiOs, from a formal viewpoint, are synthetic polymers, but this has 
already been covered in the previous section devoted to routinely used materials.  
Poly(1-vinyl-2-pyrrolidone) 
Poly(1-vinyl-2-pyrrolidone) (PVP) was the first synthetic polymer to be tested as a potential vitreous 
substitute. In the 1950s, PVP solutions with different dilution rates were injected in rabbits‘ and human 
eyes [160,161]: PVP exhibited a good biocompatibility, induced less inflammatory reactions than 
physiological solutions or air but had short retention time in the vitreous cavity; in addition, problems 
of vitreous opacification were also reported. No other studies on the use of PVP as such are available 
in the literature. The 1-vinyl-2-pyrrolidone (VP) monomer was polymerized with divynil glycol (DVG) 
as cross-linking agent, thereby obtaining a transparent (RI = 1.3390) hydrogel with density and 
viscosity very similar to those of human vitreous [162,163]. The cross-linked PVP was implanted in 
rabbits: no damage to the retina was detected, but vitreous opacification occurred; in addition, the 
polymer underwent biodegradation due to phagocytosis [164]. VP was also copolymerized with 2-
hydroxyethyl methacrylate (HEMA) using DVG or diallyl ether (DAE) as  
cross-linking agents and the resulting hydrogel was implanted in rabbits [165]. This gel was 
transparent, insoluble in water and exhibited mechanical properties close to those of natural vitreous. 
From a clinical viewpoint, no particular complications were detected after implantation, with the 
exception of transient vitreous opacities. However, the process of injection via a small-gauge needle 
caused polymer fragmentation resulting in a decrease in the hydrogel mechanical properties. In 
addition, all eyes were characterized by the presence of inflammatory cells and vacuoles containing 
granular material, which indicates that material phagocytosis occurred [164]. 
Polyacrylamide 
Acrylamide as such is known to be toxic and carcinogenic, but after careful and complete 
polymerization, the resulting polymer appears to be biocompatible; obviously, the presence of residual 
monomer can have serious effects in vivo on patients‘ health.  
A series of clinical trials concerning the use of polyacrilamide (PAA) as a vitreous substitute in 
rabbits‘ eyes were reported by Muller-Jensen et al. [166]. The monomers were polymerized directly 
inside the vitreous cavity without using cross-linking agents: irritation was observed in all cases in the 
first postoperative days and the vitreous underwent opacification at high PAA concentrations. 
However, no histological degeneration was observed within three months after implantation.  
Cross-linked PAA was also implanted in rabbits‘ eyes after in situ polymerization with better clinical 
outcomes [167]: the material was well-tolerated by tissues and remained clear during the postoperative 
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follow-up (14 months). A detailed investigation of the optical properties of cross-linked PAA was 
reported by Refojo et al. [168]. 
For many years, no further study was carried out on the use of PAA as a potential vitreous 
substitute, but recently acrylamide and bisacryloylcistamine (BAC) were copolymerized with disulfide 
cross-linking agents [169–172]. The use of disulfide cross-linkers enabled a high purification of the 
final polymer by removing all residual monomers. Two procedures are possible for implantations: the 
gels can be formed directly in the eye, or else the final polymer can be injected into the vitreous cavity 
without undergoing fragmentation or loss of elasticity and mechanical properties, as demonstrated by 
preliminary tests carried out by using cadaver human eyes. Furthermore, in vitro tests showed that the 
biocompatibility of the gel can be further improved by adding N-phenylacrylamide, i.e., a hydrophobic 
monomer [170]. This final gel is undoubtedly worthy of further investigations in vivo and is a 
promising candidate for vitreous substitution.  
Poly(Glyceryl Methacrylate) 
Refojo‘s group was the first to demonstrate the biocompatibility of PGMA in ocular tissues and to 
propose its use as a scleral buckling material—as mentioned above—and for vitreous tamponade 
[173]. Spherical pieces of dehydrated PGMA were implanted in rabbits‘ vitreous cavities through a 
small surgical incision and the implants swelled in situ after contact with vitreous fluids, thereby 
reaching postoperatively volumes up to 32-times greater than the initial ones in the dry state. No 
inflammation or postoperative complications were detected, however the hydrogel was considered 
unsuitable for clinical use as its implantation was too traumatic and its swelling was too slow and, thus, 
problems of immediate tamponade occurred. 
Hogen-Esch et al. synthesized an injectable PGMA hydrogel using very low amounts of  
cross-linking agents [174]. The gel was able to absorb up to 96%wt. of aqueous saline and, after 
swelling, remained soft and sufficiently transparent. Even if a slight loss of light transmittance was 
assessed, the final RI (1.3364) was still very close to that of natural vitreous. After implantation in 
rabbits‘ eyes, good clinical outcomes without complications were observed. However, as the hydrogel 
underwent fragmentation upon injection, no further studies were carried out on PGMA as a  
vitreous substitute.  
Poly(2-hydroxyethyl acrylate)/Poly(2-hydroxyethyl methacrylate) 
Poly(2-hydroxyethyl acrylate) (PHEA) was tested by Chan et al. [143] in rabbits‘ eyes as a potential 
vitreous substitute. PHEA exhibited excellent physical properties, such as high transparency, viscosity 
similar to that of natural vitreous, non-absorbability and easy injectability, that made it, also 
theoretically, an ideal vitreous substitute. However, clinical outcomes were not satisfactory, as PHEA 
induced corneal oedema, glaucoma, damage to the lens as well as its opacification, formation of 
fibrous membranes and severe retinal complications. 
Poly(2-hydroxyethyl methacrylate) (PHEMA) is a solid hydrogel that was well-tolerated by ocular 
tissues, did not elicit retinal damages, and did not undergo bioabsorption or biodegradation. However, 
its implantation required difficult surgical procedures and, therefore, was no longer investigated [175].  
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Silicone Gel 
Two silicone gel formulations (A = clear gel, B = hazy gel) were tested in monkeys by Peyman  
et al. [176]. The liquid monomers were injected into the vitreous cavities and polymerization occurred 
in situ. Apart from a minimal postoperative inflammation of one week, no clinical complications were 
reported. No retinal damage was detected, neither gel lost its cohesiveness and, specifically, the clear 
gel (formulation A) remained transparent over time. However, due to their hydrophobic nature, the gels 
remained separated from the retina, thereby losing any tamponade effect. Therefore, it is reasonable to 
assume that such gels are not suitable for vitreous substitution.  
Hydroxypropyl Methylcellulose 
Fernandez-Vigo et al. injected a solution of hydroxypropyl methylcellulose (HPMC)  
(viscosity ~6000 cSt, Mw = 86 kDa) in rabbits‘ eyes [177]: HPMC was completely eliminated from the 
vitreous cavity within 10 weeks after implantation and, therefore, the authors concluded in this first 
study that HPMC solutions are useful neither as a long-term vitreous substitute nor for sealing retinal 
holes in RRD due to the lack of tamponade effect. However, the excellent biocompatibility of HPMC 
was encouraging and the authors carried out another animal study in which they demonstrated that the 
residence time of HPMC in the vitreous cavity could be controlled by varying its molecular  
weight [178]. Specifically, by using a product with Mw = 120 kDa and viscosity ~6000 cSt. The  
half-life time of the substitute was 38 days; nonetheless, such a substitute is still unsuitable for 
prolonged tamponade.  
Pluronic F127 
Pluronic F127 (P-F127) solutions at a concentration ≥20%wt. show thermoreversible gelation 
behavior [179]. For instance, a 20%wt. P-F127 solution is liquid when cold, but forms a clear gel  
(RI = 1.032) at 21 °C as the solution is heated. In spite of their attractive physical properties, P-F127 
solutions were found to be unsuitable for vitreous substitution. In fact, Davidorf et al. [180] showed 
that the polymer can induce severe retinal toxicity and Dalton et al. [181] demonstrated through 
rheological studies that P-F127 is not easily injectable via a small-gauge needle into the vitreous cavity, 
thereby complicating surgical procedures. 
Poly(methyl 2-acrylamidoglycolate methyl ether) 
In the early 1990s, Chirila et al. tested several polymers derived from (methyl 2-acrylamido-
glycolate methyl ether) as a potential vitreous substitute [182]. Eventually, the homopolymer 
poly(methyl 2-acrylamidoglycolate methyl ether) (PMAGME), synthesized in 80%wt. of water and 
without cross-linking agents, was selected for in vivo tests in rabbits. Negligible fragmentation upon 
injection was observed, but severe postoperative clinical complications were reported, including retinal 
detachment, inflammation, and damage to the optic nerve. The cause of the toxic effect remained 
unclear as it could have been due to the polymer itself or, maybe more reasonably, to residual 
acrylamide, which is known to be a neurotoxic product. The authors also reported the results of in vitro 
studies using mouse fibroblast cells, that revealed the cytostatic and cytocidal effect of the hydrogel 
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[182]. This demonstrated for the first time that in vitro cytotoxicity assay can be very useful for 
performing a preliminary selection of polymers as potential vitreous substitutes. 
Poly(vinyl alcohol) 
In the early 1990s, Benlian et al. [183] selected poly(vinyl alcohol) (PVA) as a potential vitreous 
substitute on the basis of its optical properties being very similar to those of natural vitreous, and they 
evaluated its performances in rabbits‘ eyes. Postoperative outcomes were good, as no inflammation or 
damage to the retina was detected after two months of implantation. 
Yamauchi et al. [184] widely investigated autoclave-sterilized PVA hydrogels consisting of 99%wt. 
of water; the gels were produced by γ-irradiation of a 7%wt. PVA solution and then injected into 
rabbits‘ eyes. Inflammation and vitreous opacification occurred more frequently in the long-term with 
PVA than with physiological solutions. The short-time optical properties were excellent, as the gels 
were indistinguishable from the host vitreous in the first postoperative weeks. A mixture of 
PVA/chondroitin sulfate was also used: it could not be separated into components even after extraction 
with boiling water, displayed a transparency superior to that of PVA as such and absorbed more water 
than PVA alone, but it was less biocompatible in rabbits‘ eyes.  
Recently, Maruoka et al. [185] prepared PVA hydrogels by treating the polymer solution in 
autoclave before γ-irradiation (like previously reported by Yamauchi et al.) and injected the resulting 
gels into monkeys‘ eyes. During the first postoperative weeks inflammatory response and IOP increase 
was detected, but by 3 months after implantation the eyes regained normal IOP and retinal activity. Due 
to their good optical properties and long-term biocompatibility, PVA hydrogels are promising 
candidates for vitreous substitution, but further studies need to be performed to collect more data about 
their retention time, mechanical properties and ability to reattach the retina.  
Poly(vinyl alcohol methacrylate) 
Recently, Cavalieri et al. [186] carried out preliminary investigations on poly(vinyl alcohol 
methacrylate) (PVA-MA) to test its potential suitability as a vitreous substitute. The polymer contained 
a photoinitiator and the gel network could be formed by irradiation at 365 nm; the degree of 
cross-linking could be tailored by varying the photoinitiator concentration and the radiation exposure 
time. The ability of in situ gelification was an attractive property. The authors reported that gelification 
did not occur at polymer concentrations lower than 4%wt., and in vitro tests using bovine serum 
showed that hydrogel degradation occurred in the presence of a low degree of cross-linking. Therefore, 
potentially suitable hydrogels were those synthesized at high polymer concentrations and with a high 
degree of cross-linking; however, such gels were found to be significantly stiffer than natural vitreous. 
Further studies addressed at reducing this mismatch between the mechanical properties of PVA-MA 
and those of natural vitreous are needed to understand whether such a material remains a valid 
contender for vitreous substitution. 
Adcon-L hydrogel 
De Jong et al. [187] reported in one study the use of Adcon-L hydrogel (a carbohydrate-based 
hydrogel experimented successfully in neurosurgery) for vitreous substitution in rabbits‘ eyes. This 
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material is absolutely unsuitable for this purpose, as severe postoperative complications were reported, 
such as persistent inflammation, cornea opacification, damage to the lens and toxicity to the retina; in 
addition, the residence time in the vitreous cavity was very short (~three weeks). 
Semifluorinated Alkanes 
A final mention should be devoted to semifluorinated alkanes (SFAs). SFAs exhibit a chemical 
structure of the type RH—RF or RF—RH—RF, in which short alkyl chains join at one or both ends to a 
perfluorocarbon chain. SFAs are transparent and have lower density (1.1–1.7 g/cm3) than both SiOs 
and PFCLs [188–190]. At present, SFAs are used as biocompatible solvents for SiOs. In general, the 
longer the RH chain in the SFA, and the lower the viscosity of SiO, the better the solubility in each 
other. Optically clear mixtures of SiOs and SFAs, with a typical density of 1.2–1.3 g/cm3 can be 
obtained, and preliminary studies demonstrate that SFAs can be successfully used as such for unfolding 
and reattaching the retina and as long-term vitreous substitutes [188,190]. In addition, Meinert et al. 
suggested the use of SFAs as solvents for selected drugs [190]: therefore, by injecting the material into 
the vitreous cavity, it is also possible to carry out an in situ pharmaceutical therapy. SFAs exhibit great 
potential for the replacement of currently used vitreous tamponade agents, but further studies on their 
biocompatibility and in vivo behavior are still necessary. For this reason, we decided to include SFAs 
in this section of the review even though they are already commercially available and marketed for 
ophthalmic use. 
8. Summary of Current Solutions 
Depending on the type of RD and related conditions, different treatment strategies, as well as 
different materials and implants, are at the surgeon‘s disposal. 
Pneumatic retinopexy is an effective surgical procedure (success rate >90%) for most of RRDs. 
Specifically, it is useful when a single tear causes the RRD, or multiple breaks are small and close to 
each other, or else the break is in the upper part of the retina. Recent experimental work seems to 
indicate that SF6 and PFCGs led to substantially similar results both in terms of anatomic success rate 
(retinal reattachment) and as regards the development of cataract in phakic eyes [191,192]. 
In the case of multiple retinal breaks spread over a wide area, giant tears or TRD, scleral buckling or 
vitrectomy are commonly performed and these two procedures may be performed together. Today, 
silicone is considered by surgeons as the ―gold standard‖ material for manufacturing scleral  
buckles [69–75] and solid/porous silicone implants are marketed worldwide. More than seventy style 
options for silicone buckles are currently available to the ophthalmic surgeons seeking an implant 
designed to achieve a particular width, height or shape of the buckle. The evolution continues today as 
new techniques develop and surgeons identify new needs and suggest new styles to meet such needs. 
With regard to tamponade agents, suitable for vitrectomy procedures, today SiOs [123] and  
PFCLs [130] still remain the preferred choice among surgeons. SiO exhibits attractive features, e.g., 
permanent retention in the vitreous cavity, remarkable optical clarity and chemical inertness, which 
make it a promising candidate for vitreous substitution. However, there is convincing evidence that 
SiO can induce serious long-term complications such as glaucoma, corneal damage and cataract. In 
addition, the removal of SiO is generally difficult and any amount remaining may be retained 
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indefinitely. In spite of these drawbacks, in the last years there has been renewed interest toward the 
use of SiO as vitreous tamponade, stimulated by advances in surgical techniques and oil purification, 
and by the view that any above-mentioned clinical complications can be successfully treated. PFCLs, 
thanks to their excellent transparency, high density and intrinsic non-toxicity, remain an effective tool 
only for intraoperative surgical procedures, as many studies suggest that they should not be used 
postoperatively for long-term vitreous tamponade.  
Although studies previously mentioned indicate that polymer-containing aqueous solutions can only 
be suitable for short-term vitreous tamponade, (due to their dissipation into the surrounding ocular 
tissues), it is the author‘s opinion that, on the contrary, polymeric insoluble gels are very promising 
candidates for use as long-term vitreous substitutes.  
9. Future Forecasts 
In conjunction with the tremendous developments that occurred in instrument design and surgical 
techniques for RD treatment in recent years, the application of advanced materials‘ concepts for 
tailoring ocular biomaterials and implants is a particularly challenging area of research. The following 
paragraphs highlight some key points that, in the author‘s opinion, should be taken into account when 
outlining future research in the field of scleral buckling and vitreous substitution materials. 
9.1. Open Fields of Research about Scleral Buckles 
The low complication rate associated with solid and porous silicone buckles results in a low demand 
to search for alternative materials/implants to those currently available on the market. Nonetheless, 
challenging fields of research still remain to be explored in detail and have re-attracted researchers‘ 
interest in recent years, such as the development of absorbable materials suitable for temporary 
buckles. In children, for instance, the use of a permanent silicone buckle could cause severe long-term 
complications, as the ―buckling effect‖ does not allow the eye to grow physiologically; hence, the 
buckle has to be removed by a second operation. The use of an absorbable buckle manufactured using a 
synthetic biodegradable polymer could be a good option to overcome this drawback. In this context, 
PLA buckles, recently tested by Lansmann et al. in rabbits [110–112], seem to be very promising and 
worthy of clinical trials in human patients. 
Another interesting field of research concerns the development of buckles able to release drugs 
according to desired kinetics. Hydrogel-based (fallen in disuse) [54] and porous silicone (sponge) [75] 
buckles have already been proposed as depot devices for the slow release of antibiotics. The surface 
functionalization of solid silicone buckles might also be investigated in order to better control drug 
release kinetics. In situ release of anti-inflammatory drugs can contribute to further reduce some 
occasional complications, such as scleral inflammation associated to the current silicone implants.  
Finally, the author wishes to highlight a novel theme of research based on the synergy between 
materials science, medical imaging and physico-mathematical modeling. It is known that scleral 
buckling procedures induce geometric changes in the eyeball, and over indented scleral buckles can 
promote IOP rise over time, causing long-term complications such as glaucoma [193]. Recently, 
mathematical models were developed for predicting the deformation of the human eyeball caused by 
the application of an elastic band (scleral buckle) [194–196]. In particular, the model conceived by 
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Keelig et al. [196] gives results in good accordance with experimental data. By assessing the patients‘ 
initial eye geometric, physical and mechanical features through advanced techniques (MRI, high-
resolution computerized tomography, ultrasound imaging), it could be possible to simulate eye 
deformation in response to different scleral buckles, and, therefore, feasibly tailor an ―ideal‖ scleral 
buckle—in terms of material formulation, size, shape, elasticity—for each single case. As regard to 
absorbable buckles, analytical models able to predict the persistence of scleral indentation as a function 
of polymer degradation rate, as well as the modifications of implant geometry may be developed over 
time. These mathematical models could be helpful tools for surgeons to foresee and prevent 
postoperative complications as well as for optimizing the RD treatment procedure.  
9.2. Towards an Ideal Vitreous Substitute 
For years, the search for a vitreous substitute suitable for treating RD cases was primarily addressed 
to find a biocompatible fluid able to approximate the neural retina to the RPE. This has led to the 
development of several short-term vitreous tamponade agents (natural and semisynthetic polymers, 
physiological solutions), as well as gases used for pneumatic retinopexy. However, these materials 
allowed only a temporary tamponade effect, and were unsuitable for permanent vitreous replacement. 
The future of vitreous substitutes is to find a formulation that can be left in situ indefinitely without 
long-term clinical complications, such as compressive damage to cells, IOP rise and postoperative 
glaucoma. An ideal artificial vitreous should closely mimic the light transmittance of natural vitreous 
humor, as well as its physical and mechanical properties. Polymeric hydrogels seem to be promising 
materials for long-term vitreous substitution: they generally show excellent transparency, are highly 
biocompatible and can act as a viscoelatic shock-absorber, thereby closely mimicking the behavior of 
natural vitreous. By acting on the formulation and synthesis process of the hydrogel, the density and 
rigidity of the final vitreous substitute could be tailored in order to match those of natural vitreous. In 
addition, some experimentally tested hydrogels can gel after injection into the vitreous cavity; in situ 
gelation is a key point because polymers that are injected as gels rather than liquids fragment due to 
shear stress in the needle, lose their elasticity, and can cause inflammation in ocular tissues. Finally, 
hydrogels might be used as smart matrices for controlled drug release within the vitreous cavity which 
could be a very helpful tool to benefit patients suffering from intravitreal affections, such as PVR. 
On the basis of data currently available in the literature and discussed in the previous sections, the 
author suggests that four synthetic polymers seem particularly suitable for prolonged vitreous 
tamponade and worthy of further investigations: PAA [166–172], PVA [183–185], PVA-MA [186] 
and SFAs [188–190]. Also, three other materials, HPMC [177,178], the cross-linked gelatins recently 
tested by Lai [152], and the gellan gum/hyaluronic acid gel proposed by Suri et al. [159], exhibit 
interesting properties, but seem only useful for short-term vitreous substitution. 
As a final methodological remark, in the author‘s opinion it would be desirable to elaborate a 
standard and detailed protocol for selecting and testing materials proposed as potential vitreous 
substitutes. In fact, when looking at most of the existing literature, it seems very often the polymers 
were selected according to ambiguous criteria, and no systematic exploration of their long-term toxicity 
and rheological properties was carried out prior to in vivo experiments. It was therefore difficult to state 
definitive conclusions as to their suitability as vitreous substitutes. In the future, in vitro cytotoxicity 
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assays and rheological studies should be generally considered and accepted as fundamental eliminatory 
criteria in the selection of potential vitreous substitutes. 
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